ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

CanSino Biologics, Sanofi and Bayer side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

CanSino Biologics×Sanofi×Bayer×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

CanSino BiologicsSanofiBayer
studies on the registry412,4251,694
open to participants now610560
phase 3 studies under way46111
reach primary completion within a year26435
programswith a study of their own in two years1280+12 named only21

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseCanSino BiologicsSanofiBayer
Phase 150%28%19%
Phase 28%

Sanofi: 25 of its 80 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. efdoralprin alfaphase 2

and 20 more — sign in to see them all

31%

Bayer: 8 of its 21 programs at phase 2

  1. AB-1005phase 2
  2. WRN Inhibitor RO7589831phase 2
  3. nurandociguatphase 2
  4. BAY 3401016phase 2
  5. BAY 3670549phase 2

and 3 more — sign in to see them all

38%
Phase 333%

Sanofi: 22 of its 80 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

28%

Bayer: 4 of its 21 programs at phase 3

  1. elinzanetantphase 3
  2. sevabertinibphase 3
  3. bemdaneprocelphase 3
  4. aficamtenphase 3
19%
Approved, new studies

CanSino Biologics: 1 of its 12 programs at approved, new studies

  1. MCV4approved, new study
8%

Sanofi: 11 of its 80 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%

Bayer: 5 of its 21 programs at approved, new studies

  1. finerenoneapproved, new study
  2. darolutamideapproved, new study
  3. Aspirinapproved, new study
  4. acoramidisapproved, new study
  5. Levonorgestrelapproved, new study
24%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
CanSino Biologics2 readouts · 1 phase 3

CanSino Biologics, Nov ’26: 1 program whose next study reaches primary completion

  1. 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M)phase 2 · Nov 24 · NCT07600983
··

CanSino Biologics, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. 13-valent pneumococcal vaccinephase 3 · Feb 15 · NCT07017777
········
Sanofi29 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141

Sanofi, Aug ’27: 1 program whose next study reaches primary completion

  1. SAR448632phase 1 · Aug 15 · NCT07944885

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
Bayer10 readouts · 4 phase 3·

Bayer, Dec ’26: 1 program whose next study reaches primary completion

  1. BAY 3389934phase 1 · Dec 25 · NCT06854640

Bayer, Jan ’27: 1 program whose next study reaches primary completion

  1. elinzanetantphase 3 · Jan 22 · NCT07762287
·

Bayer, Mar ’27: 1 program whose next study reaches primary completion

  1. Aspirinapproved, new study · Mar 10 · NCT07652723

Bayer, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. finerenoneapproved, new study · Apr 10 · NCT05196035

Bayer, May ’27: 2 programs whose next study reaches primary completion

  1. nurandociguatphase 2 · May 7 · NCT07431294
  2. WRN Inhibitor RO7589831phase 2 · May 31 · NCT06004245
·

Bayer, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. darolutamideapproved, new study · Jul 30 · NCT05794906

Bayer, Aug ’27: 1 program whose next study reaches primary completion

  1. RAS/PI3K-alpha Inhibitor VVD-159642phase 1 · Aug 1 · NCT06804824

Bayer, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. acoramidisapproved, new study · Sep 17 · NCT07298044

Bayer, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sevabertinibphase 3 · Oct 28 · NCT06452277
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

CanSino Biologics

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Sanofi

New programs 6

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Bayer

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 9 in all. A program counts in each condition its studies name most.

ConditionCanSino BiologicsSanofiBayer
Influenza, Human2 of 3 · compare here

CanSino Biologics in Influenza, Human: 1 program

  1. 13-valent pneumococcal vaccinephase 3

Their studies: CanSino Biologics’ studies of Influenza, Human in search

–
Diphtheria2 of 3 · compare here

Sanofi in Diphtheria: 1 program

  1. DTaP-IPV-HB-PRP~T combined vaccinephase 3

Their studies: Sanofi’s studies of Diphtheria in search

–
Carcinoma, Non-Small-Cell Lung2 of 3 · compare here–

Sanofi in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Tadalafilphase 3

Their studies: Sanofi’s studies of Carcinoma, Non-Small-Cell Lung in search

Bayer in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. sevabertinibphase 3
  2. PRMT5 Inhibitor BAY 3713372phase 2

Their studies: Bayer’s studies of Carcinoma, Non-Small-Cell Lung in search

Diabetes Mellitus, Type 22 of 3 · compare here–

Sanofi in Diabetes Mellitus, Type 2: 1 program

  1. iGlarLixi (insulin glargine/lixisenatide)approved, new study

Their studies: Sanofi’s studies of Diabetes Mellitus, Type 2 in search

Bayer in Diabetes Mellitus, Type 2: 2 programs

  1. finerenoneapproved, new study
  2. Levonorgestrelapproved, new study

Their studies: Bayer’s studies of Diabetes Mellitus, Type 2 in search

Parkinson Disease2 of 3 · compare here–

Sanofi in Parkinson Disease: 1 program

  1. Biological Productsphase 1

Their studies: Sanofi’s studies of Parkinson Disease in search

Bayer in Parkinson Disease: 2 programs

  1. bemdaneprocelphase 3
  2. AB-1005phase 2

Their studies: Bayer’s studies of Parkinson Disease in search

Pneumococcal Infections2 of 3 · compare here

Sanofi in Pneumococcal Infections: 1 program

  1. Pneumococcal 21-Valent Conjugate Vaccinephase 3

Their studies: Sanofi’s studies of Pneumococcal Infections in search

–
Colorectal Neoplasms2 of 3 · compare here–

Sanofi in Colorectal Neoplasms: 1 program

  1. tusamitamab sonditecanphase 1

Their studies: Sanofi’s studies of Colorectal Neoplasms in search

Bayer in Colorectal Neoplasms: 1 program

  1. WRN Inhibitor RO7589831phase 2

Their studies: Bayer’s studies of Colorectal Neoplasms in search

Meningitis, Meningococcal2 of 3 · compare here

CanSino Biologics in Meningitis, Meningococcal: 1 program

  1. MCV4approved, new study

Their studies: CanSino Biologics’ studies of Meningitis, Meningococcal in search

Sanofi in Meningitis, Meningococcal: 1 program

  1. MenACYW conjugate vaccineapproved, new study

Their studies: Sanofi’s studies of Meningitis, Meningococcal in search

–
Pneumonia, Pneumococcal2 of 3 · compare here

CanSino Biologics in Pneumonia, Pneumococcal: 1 program

  1. 13-valent pneumococcal vaccinephase 3

Their studies: CanSino Biologics’ studies of Pneumonia, Pneumococcal in search

Sanofi in Pneumonia, Pneumococcal: 1 program

  1. Pneumococcal 21-Valent Conjugate Vaccinephase 3

Their studies: Sanofi’s studies of Pneumonia, Pneumococcal in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetCanSino BiologicsSanofiBayer
KRAS–Pan-KRAS Inhibitor BLU-924KRAS G12D Inhibitor KQB548rule
A target, or a pathogen for a vaccine, known for: CanSino Biologics 5 of 12 · Sanofi 53 of 80 · Bayer 13 of 21 programs (23 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sanofi: 12).